36 Participants Needed

Mosunetuzumab + Zanubrutinib for Lymphoma

DC
Overseen ByDai Chihara, MD,PHD
Age: 18+
Sex: Any
Trial Phase: Phase 2
Sponsor: M.D. Anderson Cancer Center
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial

Trial Summary

Will I have to stop taking my current medications?

The trial requires that you stop taking any strong CYP3A inhibitors at least 7 days before starting the study drugs. If you are on corticosteroids, you must be on a dose equivalent to less than 10 mg/day of prednisone for the last 4 weeks. Other medications are not specifically mentioned, so it's best to discuss with the trial team.

What data supports the effectiveness of the drugs Mosunetuzumab and Zanubrutinib for treating lymphoma?

Mosunetuzumab has been conditionally approved in the EU for treating relapsed or refractory follicular lymphoma, showing its potential effectiveness. Zanubrutinib, when combined with obinutuzumab, showed a 72% overall response rate in patients with relapsed or refractory follicular lymphoma, indicating it may be effective in similar conditions.12345

Is the combination of Mosunetuzumab and Zanubrutinib safe for humans?

Mosunetuzumab and Zanubrutinib have been studied separately and in combination with other drugs for different types of lymphoma. Mosunetuzumab has shown a manageable safety profile, with common side effects like cytokine release syndrome (a reaction that can cause fever and low blood pressure) and neutropenia (low white blood cell count). Zanubrutinib, when combined with other drugs, was generally well tolerated, with common side effects including infections, fatigue, and low blood cell counts.12467

How is the drug combination of Mosunetuzumab and Zanubrutinib unique for treating lymphoma?

The combination of Mosunetuzumab and Zanubrutinib is unique because Mosunetuzumab is a bispecific antibody that helps the immune system target and destroy cancer cells, while Zanubrutinib is a highly selective inhibitor that blocks a protein involved in cancer cell growth. This dual approach may offer a novel way to treat relapsed or refractory lymphoma by combining immune system engagement with targeted cancer cell inhibition.12389

What is the purpose of this trial?

To assess the efficacy and safety of mosunetuzumab combined with zanubrutinib in patients with relapsed or refractory MZL.

Research Team

Dai Chihara | MD Anderson Cancer Center

Dai Chihara, M D

Principal Investigator

M.D. Anderson Cancer Center

Eligibility Criteria

This trial is for individuals with Marginal Zone Lymphoma (MZL) who have tried other treatments that didn't work or stopped working. Specific eligibility details are not provided, but typically participants need to meet certain health standards and may be excluded based on factors like other medical conditions or treatments.

Inclusion Criteria

I can perform daily activities with minimal assistance, more if my condition is lymphoma.
My organ and bone marrow functions are within normal ranges.
I have at least 3 large tumors that are 3 cm or bigger.
See 23 more

Exclusion Criteria

I have had cancer other than B-NHL but have been free of it for over 3 years.
I have active brain or spinal cord lymphoma.
I am on long-term medication that strongly affects liver enzymes.
See 19 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive mosunetuzumab and zanubrutinib for relapsed/refractory marginal zone lymphoma

12 months

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

Treatment Details

Interventions

  • Mosunetuzumab
  • Zanubrutinib
Trial Overview The trial is testing the combination of two drugs: Mosunetuzumab and Zanubrutinib, in patients with MZL that has come back after treatment or hasn't responded to previous therapies. It's a Phase 2 trial, which means it focuses on the effectiveness and safety of this drug combo.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: Treatment w/Mosunetuzumab + ZanubrutinibExperimental Treatment2 Interventions

Mosunetuzumab is already approved in European Union, United States for the following indications:

🇪🇺
Approved in European Union as Lunsumio for:
  • Relapsed or refractory follicular lymphoma after two or more lines of systemic therapy
🇺🇸
Approved in United States as Lunsumio for:
  • Relapsed or refractory follicular lymphoma after two or more lines of systemic therapy

Find a Clinic Near You

Who Is Running the Clinical Trial?

M.D. Anderson Cancer Center

Lead Sponsor

Trials
3,107
Recruited
1,813,000+

Findings from Research

Mosunetuzumab, a bispecific antibody targeting CD20 and CD3, has received conditional approval in the EU for treating adults with relapsed or refractory follicular lymphoma after at least two prior therapies.
This approval marks a significant milestone in the development of mosunetuzumab, highlighting its potential as a new treatment option for patients with difficult-to-treat lymphoma.
Mosunetuzumab: First Approval.Kang, C.[2022]
In a phase II study involving 217 patients with relapsed/refractory follicular lymphoma, the combination of zanubrutinib and obinutuzumab (ZO) showed a significantly higher overall response rate (ORR) of 69% compared to 46% for obinutuzumab alone, indicating greater efficacy.
The safety profile of ZO was manageable, with common side effects including thrombocytopenia and neutropenia, and serious adverse events like atrial fibrillation occurring in only 3% of patients, suggesting that ZO could be a promising treatment option for this patient population.
ROSEWOOD: A Phase II Randomized Study of Zanubrutinib Plus Obinutuzumab Versus Obinutuzumab Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma.Zinzani, PL., Mayer, J., Flowers, CR., et al.[2023]
In the phase 3 SEQUOIA trial involving adult patients with treatment-naïve chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), zanubrutinib significantly improved progression-free survival compared to the standard treatment of bendamustine plus rituximab (BR).
Patients treated with zanubrutinib reported better health-related quality-of-life outcomes at 12 and 24 weeks, including improvements in global health status, physical functioning, and reduced symptoms of diarrhea, fatigue, and nausea/vomiting compared to those receiving BR.
Health-related quality-of-life in treatment-naive CLL/SLL patients treated with zanubrutinib versus bendamustine plus rituximab.Ghia, P., Barnes, G., Yang, K., et al.[2023]

References

Mosunetuzumab: First Approval. [2022]
ROSEWOOD: A Phase II Randomized Study of Zanubrutinib Plus Obinutuzumab Versus Obinutuzumab Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma. [2023]
Health-related quality-of-life in treatment-naive CLL/SLL patients treated with zanubrutinib versus bendamustine plus rituximab. [2023]
Zanubrutinib (BGB-3111) plus obinutuzumab in patients with chronic lymphocytic leukemia and follicular lymphoma. [2021]
Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial. [2023]
Mosunetuzumab in combination with CHOP in previously untreated DLBCL: safety and efficacy results from a phase 2 study. [2023]
Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b/2 trial. [2023]
Zanubrutinib Monotherapy for Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Pooled Analysis of Three Studies. [2022]
Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study. [2023]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security